Zanubrutinib Clinical Trials
50 recruitingDrug
Phase 235Phase 19Phase 36Phase 42
Showing 1–20 of 50 trials
Recruiting
Phase 3
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
BeOne Medicines500 enrolled91 locationsNCT07277231
Recruiting
Phase 2
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
Lymphoma
M.D. Anderson Cancer Center36 enrolled1 locationNCT06563505
Recruiting
Phase 1Phase 2
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Refractory CancerB-cell LymphomaB-cell Malignancy+1 more
BeOne Medicines80 enrolled50 locationsNCT06634589
Recruiting
Phase 3
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Mantle Cell LymphomaB-cell Lymphoma
BeOne Medicines300 enrolled155 locationsNCT06742996
Recruiting
Phase 2
Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma (SLL)
Massachusetts General Hospital80 enrolled2 locationsNCT06849713
Recruiting
Phase 2
Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
Ann Arbor Stage II Follicular LymphomaGrade 1 Follicular LymphomaAnn Arbor Stage III Follicular Lymphoma+3 more
Chinese PLA General Hospital30 enrolled1 locationNCT06471738
Recruiting
Phase 3
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology421 enrolled237 locationsNCT05976763
Recruiting
Phase 2
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
Mantle Cell Lymphoma
Canadian Cancer Trials Group40 enrolled3 locationsNCT07341191
Recruiting
Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Waldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma
National Cancer Institute (NCI)92 enrolled136 locationsNCT04840602
Recruiting
Phase 3
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Chronic Lymphocytic LeukemiaSmall Lymphocytic Leukemia
Alliance for Clinical Trials in Oncology466 enrolled152 locationsNCT07321652
Recruiting
Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Marginal Zone LymphomaRelapsed/Refractory Follicular Lymphoma
BeOne Medicines780 enrolled277 locationsNCT05100862
Recruiting
Phase 2
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Chronic Lymphocytic LeukemiaB-cell Malignancies
Curis, Inc.108 enrolled11 locationsNCT07271667
Recruiting
Phase 2
Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
Waldenstrom Macroglobulinemia
Massachusetts General Hospital56 enrolled5 locationsNCT06561347
Recruiting
Phase 1Phase 2
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Chronic Lymphocytic LeukemiaMantle Cell LymphomaCLL+1 more
BeOne Medicines258 enrolled17 locationsNCT06697184
Recruiting
Phase 2
A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T
Large B-cell Lymphoma
University Health Network, Toronto76 enrolled1 locationNCT06167785
Recruiting
Phase 2
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
LymphomaFollicular Lymphoma
Memorial Sloan Kettering Cancer Center152 enrolled9 locationsNCT05389293
Recruiting
Phase 1
Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma
CNS Lymphoma
Juan P. Alderuccio, MD20 enrolled1 locationNCT06730542
Recruiting
Phase 2
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
Mantle Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China37 enrolled2 locationsNCT07261163
Recruiting
Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Leukemia (SLL)
Memorial Sloan Kettering Cancer Center230 enrolled8 locationsNCT03824483
Recruiting
Phase 2
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Chronic Lymphocytic LeukemiaMantle Cell LymphomaRecurrent Chronic Lymphocytic Leukemia+6 more
Fred Hutchinson Cancer Center30 enrolled1 locationNCT06839053